| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 6, 2026 | ±6.3% | -9.7% | under-priced |
| November 6, 2025 | ±2.7% | +2.9% | under-priced |
| August 7, 2025 | ±2.5% | +9.5% | under-priced |
| May 9, 2025 | ±3.0% | +20.9% | under-priced |
| November 8, 2024 | ±3.5% | +9.4% | under-priced |
| August 9, 2024 | ±5.1% | -8.8% | under-priced |
| May 10, 2024 | ±3.5% | -6.5% | under-priced |
| November 3, 2023 | ±5.4% | +15.8% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $1.30 | $762M | $91M |
| Q4 FY2025 | $1.43 | $784M | $102M |
| Q3 FY2025 | $1.24 | $706M | $88M |
| Q2 FY2025 | $0.32 | $649M | $23M |
Insulet Corporation (PODD) reports in 98 days, with the next report estimated for September 19, 2026. Across the last 8 reports, options priced an average ±4.0% earnings move while the stock actually moved 10.4% on average — the market has tended to under-price PODD's earnings risk. Fundamentals into the print: EPS up 160.0% year-over-year, revenue up 33.9%. QuantLogix's live 5-factor engine currently reads PODD as a neutral at 49/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →